Vemurafenib selective BRAFV600E kinase inhibitor; an antitumor agent. Vemurafenib functions by inhibiting the proliferation and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and ERK phosphorylation in a panel of tumor cell lines, including melanoma cell lines expressing BRAFV600E or other mutant BRAF proteins altered at codon 600.
Melting Point:
As Reported
Solubility:
As Reported
Method for Determining Identity:
Proton NMR (CD3OD and DMSO-d6), 19F NMR (CD3OD) Spectroscopic and Mass Spectrometric Analysis
TLC Conditions:
As Reported
Ethyl Acetate:
As Reported
Storage and Stability:
May be stored at RT for short-term only. Long-term storage is recommended at 4 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Toxicity and Hazards: